NRX Pharmaceuticals (NRXP) Receivables - Net (2020 - 2026)

NRX Pharmaceuticals (NRXP) posted quarterly Receivables - Net of $362000.0 for Q1 2026, up 124.84% quarter-over-quarter from $161000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Receivables - Net (2020 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has reported Receivables - Net for 6 consecutive years, with $362000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables - Net changed N/A year-over-year to $362000.0; the TTM figure through Mar 2026 stood at $362000.0 (changed N/A YoY), while the FY2025 annual figure was $161000.0, changed N/A from the prior year.
Receivables - Net advanced to $362000.0 in Q1 2026 per NRXP's latest filing, from $161000.0 in the prior quarter.
Across five years, Receivables - Net topped out at $362000.0 in Q1 2026 and bottomed at $6000.0 in Q1 2023.
Historically, Receivables - Net has averaged $118000.0 across 5 years, with a median of $6000.0 in 2023.
Annual changes were most pronounced in 2023 — Receivables - Net tumbled 97.78% — and 2024, when it changed 0.0%.
NRX Pharmaceuticals' Receivables - Net stood at $270000.0 in 2022, then sank by 97.78% to $6000.0 in 2023, then changed by 0.0% to $6000.0 in 2024, then soared by 2583.33% to $161000.0 in 2025, then jumped by 124.84% to $362000.0 in 2026.
Business Quant data shows NRXP's Receivables - Net at $362000.0 in Q1 2026, $161000.0 in Q4 2025, and $239000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	NRX Pharmaceuticals	132.53 Mn	105.83 Mn	426,000.00

Download Data